THC Farmaceuticals, Inc (CBDG) Fair Value & Analysis
Healthcare · US · Market cap $199K
THC Farmaceuticals, Inc
CBDG · US
Fair value as of: Jul 29, 2026
From 5 valuation models · updated 12 days ago
Fair value updated Jul 29, 2026, revised from $0.0111 to $0.0076 (−31.8%) since Jun 26, 2026. Share price +287.5% over the past month.
A solid business, but screening 73% overvalued on our models.
What matters now
- The price sits above even our optimistic bull case ($0.0076). The favourable scenario is already priced in.
- The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.
- Solid but not exceptional quality (63/100) and above fair value, neither a clear bargain nor a standout compounder.
- The models converge in a tight band ($0.0073 to $0.0076), unusually little disagreement for a valuation.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 29, 2026.
How to read this chart
60‑month range $0.0002 – $0.3480 · fair‑value band $0.0073 – $0.0076 · the $0.0279 price screens above the $0.0076 fair value. Dashed = 300-day average. As of Jul 29, 2026.
Analysis
THC Farmaceuticals, Inc (CBDG) currently trades at $0.0279, while our model-based Fair Value estimate is $0.0076, implying the stock looks roughly 72.8% overvalued today. The Quality Score stands at 63/100 (solid quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: low).
Trailing-twelve-month revenue stands at $18.5K. Revenue grew 3.0% year over year. It earns a return on equity of -14.9%. Fundamentals as of Jul 29, 2026
Our scenario range runs from $0.0073 (bear case) to $0.0076 (bull case); at $0.0279, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 70% below its 52-week high, currently above its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -43% fair-value upside, at -73%, CBDG screens richer than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 5 models by family
Widest divergence: Growth DCF ($0.0130) versus Asset-Based ($0.0025). Highest evidence: Growth DCF (80).
Notify me when CBDG reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
Figures from reported company fundamentals · as of Jul 29, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 64 · Market factors (momentum, volatility) 65
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
THC Farmaceuticals, Inc. owns and operates non-financial institution cash-dispensing automated teller machines at third-party owned retail and commercial locations. The company's machines are placed in hotels, stores, bowling alleys, and other high customer traffic areas for small and medium sized businesses.
Full company description
THC Farmaceuticals, Inc. owns and operates non-financial institution cash-dispensing automated teller machines at third-party owned retail and commercial locations. The company's machines are placed in hotels, stores, bowling alleys, and other high customer traffic areas for small and medium sized businesses. As of June 30, 2015, it had a total of eight machines for public use along the Wasatch Front in the State of Utah. The company was formerly known as City Media, Inc. and changed its name to THC Farmaceuticals, Inc. in February 2015. THC Farmaceuticals, Inc. was founded in 2008 and is based in Scottsdale, Arizona. THC Farmaceuticals, Inc. operates as a subsidiary of Weed Growth Fund, Inc.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2018 – FY2025 · reported fiscal years
THC Farmaceuticals, Inc reported revenue of $10.0K in FY2022 versus $12.2K in FY2018, a compound −4.9%/yr. Reported net income was −$10.4K in FY2025.
CBDG screens 73% overvalued. Compare with Vertex Pharmaceuticals Incorporated →
Peer Group
Biotechnology · 601 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Biotechnology median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
VALUE 0: the price sits above our fair-value range.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Biotechnology stocks, each showing price versus our Fair Value estimate (as of Jul 29, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Vertex Pharmaceuticals Incorporated VRTX | $486.03 | $278.78 | -43% |
| Regeneron Pharmaceuticals, Inc REGN | $664.45 | $594.40 | -11% |
| Samsung Biologics Co 207940 | 1,368,000 KRW | 1,091,384 KRW | -20% |
| Celltrion, Inc 068270 | 175,800 KRW | 76,325 KRW | -57% |
| WuXi Biologics (Cayman) Inc 2269 | HK$39.54 | HK$30.42 | -23% |
| Innovent Biologics, Inc 1801 | HK$86.70 | HK$19.66 | -77% |
| Sino Biopharmaceutical Limited 1177 | HK$5.26 | HK$3.36 | -36% |
| ALTEOGEN Inc 196170 | 276,500 KRW | 44,444 KRW | -84% |
| RemeGen Co 688331 | ¥134.02 | ¥26.99 | -80% |
| Biocon Limited BIOCON | ₹440.70 | ₹57.36 | -87% |
Compare THC Farmaceuticals, Inc with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is THC Farmaceuticals, Inc (CBDG) overvalued or undervalued?
What is the fair value of CBDG?
What is the quality score of CBDG?
What is the revenue of THC Farmaceuticals, Inc (CBDG)?
What is the net profit margin of CBDG?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track THC Farmaceuticals, Inc and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.